Skip to content
2000
Volume 7, Issue 1
  • ISSN: 2666-7967
  • E-ISSN: 2666-7975

Abstract

Background

Since the Coronavirus Disease 2019 (COVID-19) outbreak, clinicians have been seeking alternative therapies to improve patient conditions due to limited ventilator availability. The use of high-flow nasal cannula (HFNC) remains a debate regarding its potential to reduce intubation rates or worsen patient conditions.

Objective

The objective of this study was to analyze the effect of HFNC on ventilator usage in severe to critical COVID-19 patients.

Methods

This is an observational analytical study with a retrospective cohort design using medical record data of patients with severe to critical COVID-19 at Airlangga University Hospital from March, 2021 to August, 2021.

Results

Out of 137 data, no significant relationship was found between the use of HFNC and ventilator usage in severe to critical COVID-19 patients (-value=0.337). The difference in oxygen therapy has a significant impact on patient survival rates and duration of patient care (-value=<0.001).

Conclusion

This study included 137 research samples: 69 males and 68 females, with an average age of 52.3 years, the majority presenting with diabetes and hypertension. Common symptoms included dyspnea, cough, and fever. Physical examination showed an average heart rate (HR) of 104 bpm, median respiratory rate (RR) of 30 breaths/minute, median blood oxygen level (SpO) of 86%, average systolic blood pressure (SBP) of 138 mmHg, median diastolic blood pressure (DBP) of 80 mmHg, and median body temperature of 37.5°C. The median duration of patient care in this study was 8 days. No significant influence was reported between the use of HFNC and ventilator usage in severe to critical COVID-19 patients. A significant impact of HFNC administration on patient survival rates and duration of patient care was also reported.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/covid/10.2174/0126667975306720240916062304
2024-09-26
2026-01-01

  • From This Site

    /content/journals/covid/10.2174/0126667975306720240916062304
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. MohamadianM. ChitiH. ShoghliA. BiglariS. ParsamaneshN. EsmaeilzadehA. COVID‐19: Virology, biology and novel laboratory diagnosis.J. Gene Med.2021232e330310.1002/jgm.330333305456
     [Google Scholar]
  2. DhamaK. KhanS. TiwariR. Coronavirus disease 2019–COVID-19.Clin. Microbiol. Rev.2020334e00028e2010.1128/CMR.00028‑2032580969
     [Google Scholar]
  3. AbdelrahmanZ. LiM. WangX. Comparative review of SARS-CoV-2, SARS-CoV, MERS-CoV, and influenza a respiratory viruses.Front. Immunol.20201155290910.3389/fimmu.2020.55290933013925
     [Google Scholar]
  4. ZhuZ. LianX. SuX. WuW. MarraroG.A. ZengY. From SARS and MERS to COVID-19: A brief summary and comparison of severe acute respiratory infections caused by three highly pathogenic human coronaviruses.Respir. Res.202021122410.1186/s12931‑020‑01479‑w32854739
     [Google Scholar]
  5. RenuK. PrasannaP.L. Valsala GopalakrishnanA. Coronaviruses pathogenesis, comorbidities and multi-organ damage – A review.Life Sci.202025511783910.1016/j.lfs.2020.11783932450165
     [Google Scholar]
  6. WorobeyM. Dissecting the early COVID-19 cases in Wuhan.Science2021374657212021204
     [Google Scholar]
  7. KumarA. SinghR. KaurJ. Wuhan to world: the COVID-19 pandemic.Front. Cell. Infect. Microbiol.20211159620110.3389/fcimb.2021.59620133859951
     [Google Scholar]
  8. CucinottaD. VanelliM. WHO declares COVID-19 a pandemic.Acta Biomed.2020911157160[PMID: 32191675
     [Google Scholar]
  9. da Rosa MesquitaR. Francelino SilvaL.C.Junior Santos SantanaF.M. Clinical manifestations of COVID-19 in the general population: Systematic review.Wien. Klin. Wochenschr.20211337-837738210.1007/s00508‑020‑01760‑433242148
     [Google Scholar]
  10. BajJ. Karakuła-JuchnowiczH. TeresińskiG. COVID-19: Specific and non-specific clinical manifestations and symptoms: the current state of knowledge.J. Clin. Med.202096175310.3390/jcm906175332516940
     [Google Scholar]
  11. TsaiP.H. LaiW.Y. LinY.Y. Clinical manifestation and disease progression in COVID-19 infection.J. Chin. Med. Assoc.20218413810.1097/JCMA.000000000000046333230062
     [Google Scholar]
  12. AttawayA.H. ScheragaR.G. BhimrajA. BiehlM. HatipoğluU. Severe COVID-19 pneumonia: pathogenesis and clinical management.BMJ2021372436
     [Google Scholar]
  13. GattinoniL. GattarelloS. SteinbergI. COVID-19 pneumonia: Pathophysiology and management.Eur. Respir. Rev.20213016221013810.1183/16000617.0138‑202134670808
     [Google Scholar]
  14. KumarA. AroraA. SharmaP. Clinical features of COVID-19 and factors associated with severe clinical course: a systematic review and meta-analysis.SSRN [Preprint]20203566166
     [Google Scholar]
  15. GibsonP.G. QinL. PuahS.H. COVID‐19 acute respiratory distress syndrome (ARDS): Clinical features and differences from typical pre‐ COVID‐19 ARDS.Med. J. Aust.202021325456.e110.5694/mja2.5067432572965
     [Google Scholar]
  16. BatahS.S. FabroA.T. Pulmonary pathology of ARDS in COVID-19: A pathological review for clinicians.Respir. Med.202117610623910.1016/j.rmed.2020.10623933246294
     [Google Scholar]
  17. FerrandoC. Suarez-SipmannF. Mellado-ArtigasR. Clinical features, ventilatory management, and outcome of ARDS caused by COVID-19 are similar to other causes of ARDS.Intensive Care Med.202046122200221110.1007/s00134‑020‑06192‑232728965
     [Google Scholar]
  18. DjalanteR. LassaJ. SetiamargaD. SudjatmaA. IndrawanM. HaryantoB. Review and analysis of current responses to COVID-19 in Indonesia.Prog. Disaster Sci.20206100091
     [Google Scholar]
  19. RozaliyaniA. SavitriA.I. SetianingrumF. Factors associated with death in COVID-19 patients in Jakarta, Indonesia: an epidemiological study.Acta Med. Indones.2020523246254[PMID: 33020335
     [Google Scholar]
  20. HikmawatiI. SetiyabudiR. Epidemiology of COVID-19 in Indonesia: Common source and propagated source as a cause for outbreaks.J. Infect. Dev. Ctries.202115564665210.3855/jidc.1424034106887
     [Google Scholar]
  21. NugrahaB. WahyuniL.K. LaswatiH. KusumastutiP. TulaarA.B.M. GutenbrunnerC. COVID-19 pandemic in Indonesia: Situation and challenges of rehabilitation medicine in Indonesia.Acta Med. Indones.2020523299305[PMID: 33020342
     [Google Scholar]
  22. HelmiM. SariD. MelialaA. TrisnantoroL. What is preparedness and capacity of intensive care service in Indonesia to response to covid-19? A mixed-method study.Open Access Maced. J. Med. Sci.2021916861694
     [Google Scholar]
  23. MahendradhataY. AndayaniN.L. HasriE.T. The capacity of the Indonesian healthcare system to respond to COVID-19.Front. Public Health2021964981910.3389/fpubh.2021.64981934307272
     [Google Scholar]
  24. WirawanI.M. JanuragaP.P. Forecasting COVID-19 transmission and healthcare capacity in Bali, Indonesia.J. Prev. Med. Public Health202053315816310.3961/jpmph.20.15232498137
     [Google Scholar]
  25. ProcopioG. CancelliereA. TrecarichiE.M. Oxygen therapy via high flow nasal cannula in severe respiratory failure caused by SARS-CoV-2 infection: A real-life observational study.Ther. Adv. Respir. Dis.202014175346662096301610.1177/175346662096301633070706
     [Google Scholar]
  26. PratiwiM.A. MuhlisinA. A clinical review of using a high-flow nasal cannula for patients with COVID-19 infection.J Holistic Nurs Sci202292657010.31603/nursing.v9i1.5596
     [Google Scholar]
  27. NishimuraM. High-flow nasal cannula oxygen therapy in adults: Physiological benefits, indication, clinical benefits, and adverse effects.Respir. Care201661452954110.4187/respcare.0457727016353
     [Google Scholar]
  28. YauC.E. LeeD.Y. VasudevanA. Performance of the ROX index in predicting high flow nasal cannula failure in COVID-19 patients: A systematic review and meta-analysis.Crit. Care202327132010.1186/s13054‑023‑04567‑737605238
     [Google Scholar]
  29. RocaO. MessikaJ. CaraltB. Predicting success of high-flow nasal cannula in pneumonia patients with hypoxemic respiratory failure: The utility of the ROX index.J. Crit. Care20163520020510.1016/j.jcrc.2016.05.02227481760
     [Google Scholar]
  30. MukhtarA. RadyA. HasaninA. Admission SpO2 and ROX index predict outcome in patients with COVID-19.Am. J. Emerg. Med.20215010611010.1016/j.ajem.2021.07.04934332217
     [Google Scholar]
  31. NugrahaP.K. UtarianiA. SetiawanP. SemediB.P. ROX index as a predictor of intubation risk and 28-day mortality in COVID-19 patients with acute respiratory distress syndrome.Diabetes2022344245
     [Google Scholar]
  32. FergusonN.D. FanE. CamporotaL. The Berlin definition of ARDS: An expanded rationale, justification, and supplementary material.Intensive Care Med.201238101573158210.1007/s00134‑012‑2682‑122926653
     [Google Scholar]
  33. EsanA. HessD.R. RaoofS. GeorgeL. SesslerC.N. Severe hypoxemic respiratory failure: Part 1--ventilatory strategies.Chest201013751203121610.1378/chest.09‑241520442122
     [Google Scholar]
  34. CuschieriS. The STROBE guidelines.Saudi J. Anaesth.20191353110.4103/sja.SJA_543_1830930717
     [Google Scholar]
  35. IBM SPSS Statistics for Mac2019Available from: https://www.ibm.com/products/spss-statistics
  36. GarciaW.P.D. Aguirre-BermeoH. BuehlerP.K. Implications of early respiratory support strategies on disease progression in critical COVID-19: A matched subanalysis of the prospective RISC-19-ICU cohort.Crit. Care202125117510.1186/s13054‑021‑03580‑y34034782
     [Google Scholar]
  37. LeeH.J. KimJ. ChoiM. Early intubation and clinical outcomes in patients with severe COVID-19: A systematic review and meta-analysis.Eur. J. Med. Res.202227122610.1186/s40001‑022‑00841‑636329482
     [Google Scholar]
  38. GrotbergJ.C. KraftB.D. Timing of intubation in COVID-19: When it is too early and when it is too late.Crit. Care Explor.202352e086310.1097/CCE.000000000000086336817964
     [Google Scholar]
  39. ChavarriaA.P. LezamaE.S. NavarroM.G. High-flow nasal cannula therapy for hypoxemic respiratory failure in patients with COVID-19.Ther. Adv. Infect. Dis.202182049936121104296010.1177/2049936121104295934497714
     [Google Scholar]
  40. BonnesenB. JensenJ.U. JeschkeK.N. Management of COVID-19-associated acute respiratory failure with alternatives to invasive mechanical ventilation: High-flow oxygen, continuous positive airway pressure, and noninvasive ventilation.Diagnostics20211112225910.3390/diagnostics1112225934943496
     [Google Scholar]
  41. AlshahraniM. AlshaqaqH. AlhumaidJ. High-Flow nasal cannula treatment in patients with COVID-19 acute hypoxemic respiratory failure: A prospective cohort study.Saudi J. Med. Med. Sci.20219321522210.4103/sjmms.sjmms_316_2134667467
     [Google Scholar]
  42. OczkowskiS. ErganB. BosL. ERS clinical practice guidelines: High-flow nasal cannula in acute respiratory failure.Eur. Respir. J.2022594210157410.1183/13993003.01574‑202134649974
     [Google Scholar]
  43. FratJ.P. ThilleA.W. MercatA. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure.N. Engl. J. Med.2015372232185219610.1056/NEJMoa150332625981908
     [Google Scholar]
  44. JentzerJ. DezfulianC. EmletL. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure: The FLORALI study.F1000 Res.201654110.12688/f1000research.7360.1
     [Google Scholar]
  45. MauriT. TurriniC. EroniaN. Physiologic effects of high-flow nasal cannula in acute hypoxemic respiratory failure.Am. J. Respir. Crit. Care Med.201719591207121510.1164/rccm.201605‑0916OC27997805
     [Google Scholar]
  46. MariniJ.J. GattinoniL. Management of COVID-19 respiratory distress.JAMA2020323222329233010.1001/jama.2020.682532329799
     [Google Scholar]
  47. GriecoD.L. MengaL.S. RaggiV. Physiological comparison of high-flow nasal cannula and helmet noninvasive ventilation in acute hypoxemic respiratory failure.Am. J. Respir. Crit. Care Med.2020201330331210.1164/rccm.201904‑0841OC31687831
     [Google Scholar]
  48. SchifinoG. VegaM.L. PisaniL. Effects of non-invasive respiratory supports on inspiratory effort in moderate-severe COVID-19 patients. A randomized physiological study.Eur. J. Intern. Med.202210011011810.1016/j.ejim.2022.04.01235483993
     [Google Scholar]
  49. RittayamaiN. PhuangchoeiP. TscheikunaJ. PraphruetkitN. BrochardL. Effects of high-flow nasal cannula and non-invasive ventilation on inspiratory effort in hypercapnic patients with chronic obstructive pulmonary disease: a preliminary study.Ann. Inten Care20199112210.1186/s13613‑019‑0597‑531641959
     [Google Scholar]
  50. KimB.K. KimS. KimC.Y. Factors associated with failure of high-flow nasal cannula.Respir. Care20206591276128410.4187/respcare.0740332209713
     [Google Scholar]
  51. GouryA. MoussanangJ.A. BardM. Predictive factors associated with high‐flow nasal cannula success for COVID‐19‐related acute hypoxemic respiratory failure.Health Sci. Rep.202142e28710.1002/hsr2.28733977167
     [Google Scholar]
  52. KimN.Y. ShinJ.S. JeongO.J. KimW.Y. Factors associated with unsuccessful high-flow nasal cannula therapy in patients presenting to the emergency department for acute hypoxemic respiratory failure.Int. Emerg. Nurs.20236610123610.1016/j.ienj.2022.10123636571929
     [Google Scholar]
  53. BettersK.A. GillespieS.E. MillerJ. KotzbauerD. HebbarK.B. High flow nasal cannula use outside of the ICU; factors associated with failure.Pediatr. Pulmonol.201752680681210.1002/ppul.2362627870384
     [Google Scholar]
  54. LunC.T. LeungC.K. ShumH.P. SoS.O. Predictive factors for high-flow nasal cannula failure in acute hypoxemic respiratory failure in an intensive care unit.Lung India202239151110.4103/lungindia.lungindia_122_2134975046
     [Google Scholar]
  55. LiJ. FinkJ.B. EhrmannS. High-flow nasal cannula for COVID-19 patients: Low risk of bio-aerosol dispersion.Eur. Respir. J.2020555200089210.1183/13993003.00892‑202032299867
     [Google Scholar]
  56. MartiS. CarsinA.E. SampolJ. Higher mortality and intubation rate in COVID-19 patients treated with noninvasive ventilation compared with high-flow oxygen or CPAP.Sci. Rep.2022121652710.1038/s41598‑022‑10475‑735444251
     [Google Scholar]
  57. LiY. LiC. ChangW. LiuL. High-flow nasal cannula reduces intubation rate in patients with COVID-19 with acute respiratory failure: A meta-analysis and systematic review.BMJ Open2023133e06787910.1136/bmjopen‑2022‑06787936997243
     [Google Scholar]
  58. Le PapeS. SavartS. ArrivéF. High-flow nasal cannula oxygen versus conventional oxygen therapy for acute respiratory failure due to COVID-19: A systematic review and meta-analysis.Ann. Inten Care202313111410.1186/s13613‑023‑01208‑837994981
     [Google Scholar]
  59. Ait HamouZ. LevyN. CharpentierJ. MiraJ.P. JammeM. JozwiakM. Use of high-flow nasal cannula oxygen and risk factors for high-flow nasal cannula oxygen failure in critically-ill patients with COVID-19.Respir. Res.202223132910.1186/s12931‑022‑02231‑236463161
     [Google Scholar]
  60. FratJ.P. MarchassonL. ArrivéF. CoudroyR. High-flow nasal cannula oxygen therapy in acute hypoxemic respiratory failure and COVID-19-related respiratory failure.J. Intensive Med.202331202610.1016/j.jointm.2022.07.00536756183
     [Google Scholar]
  61. LeeiesM. RosychukR.J. IsmathM. Intubation practices and outcomes for patients with suspected or confirmed COVID-19: A national observational study by the Canadian COVID-19 Emergency Department Rapid Response Network (CCEDRRN).CJEM202325433534310.1007/s43678‑023‑00487‑137017802
     [Google Scholar]
  62. ForoughiP. VarshochiM. HassanpourM. AminiB. NikniazZ. AminiH. The Predictive role of age and the systemic inflammation indexes on icu admission and mortality in patients with COVID-19.Int J Aging202311e10e010.34172/ija.2023.e10
     [Google Scholar]
  63. ShahsavariniaK. GhojazadehM. GhabousianA. HatefniaF. SoleimanpourM. SoleimanpourH. An umbrella review of clinical efficacy and adverse cardiac events associated with hydroxychloroquine or chloroquine with or without azithromycin in patients with COVID-19.Anesth. Pain Med.2021114e11582710.5812/aapm.11582734692436
     [Google Scholar]
  64. SoyyigitS. ErenE. Global supply and demand of medical ventilators in the fight against COVID-19: A network analysis.Asia-Pac J Reg Sci20226312211247
     [Google Scholar]
  65. LaurenC. IskandarA. ArgieD. Strategy within limitations during COVID-19 pandemic in Indonesia: Shortage of PPE, prevention, and neurosurgery practice.Bali Med J20209381681810.15562/bmj.v9i3.1825
     [Google Scholar]
  66. SetiatiS. AzwarM.K. COVID-19 and Indonesia.Acta Med. Indones.20205218489[PMID: 32291377
     [Google Scholar]
  67. NishikimiM. JafariD. SinghN. Mortality of mechanically ventilated COVID-19 patients in traditional versus expanded intensive care units in New York.Ann. Am. Thorac. Soc.20221981346135410.1513/AnnalsATS.202106‑705OC35213292
     [Google Scholar]
  68. BagiH.M. SoleimanpourM. AbdollahiF. SoleimanpourH. Evaluation of clinical outcomes of patients with mild symptoms of coronavirus disease 2019 (COVID-19) discharged from the emergency department.PLoS One20211610e025869710.1371/journal.pone.025869734673806
     [Google Scholar]
  69. SharmaJ. RajputR. BhatiaM. AroraP. SoodV. Clinical predictors of COVID-19 severity and mortality: A perspective.Front. Cell. Infect. Microbiol.20211167427710.3389/fcimb.2021.67427734760713
     [Google Scholar]
  70. RidjabD.A. IvanI. BudimanF. JuzarD.A. Outcome in early vs late intubation among COVID-19 patients with acute respiratory distress syndrome: An updated systematic review and meta-analysis.Sci. Rep.20221212158810.1038/s41598‑022‑26234‑736517555
     [Google Scholar]
  71. GohK.J. ChoongM.C. CheongE.H. Rapid progression to acute respiratory distress syndrome: Review of current understanding of critical illness from coronavirus disease 2019 (COVID-19) infection.Ann. Acad. Med. Singap.202049310811810.47102/annals‑acadmedsg.20205732200400
     [Google Scholar]
  72. FengZ. YuQ. YaoS. Early prediction of disease progression in COVID-19 pneumonia patients with chest CT and clinical characteristics.Nat. Commun.2020111496810.1038/s41467‑020‑18786‑x33009413
     [Google Scholar]
  73. YangL. LiuS. LiuJ. COVID-19: Immunopathogenesis and immunotherapeutics.Signal Transduct. Target. Ther.20205112810.1038/s41392‑020‑00243‑232712629
     [Google Scholar]
/content/journals/covid/10.2174/0126667975306720240916062304
Loading
The Effect of High Flow Nasal Cannula (HFNC) on the Use of Ventilators in Severe to Critical COVID-19 Patients
Coronaviruses 7, E26667975306720 (2026); https://doi.org/10.2174/0126667975306720240916062304
/content/journals/covid/10.2174/0126667975306720240916062304
/content/journals/covid/10.2174/0126667975306720240916062304
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): COVID-19; heart rate; HFNC; high flow nasal cannula; systolic blood pressure; ventilators

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test